Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer

(MedPage Today) -- SAN DIEGO -- Rucaparib (Rubraca) maintenance after first- or second-line chemotherapy improved progression-free survival (PFS) in patients with metastatic or recurrent endometrial cancer, a small phase II randomized trial showed...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news